Company Quick10K Filing
Lexaria Bioscience
10-Q 2020-11-30 Filed 2021-01-14
S-1 2020-11-20 Public Filing
10-K 2020-08-31 Filed 2020-10-15
S-1 2020-06-03 Public Filing
10-Q 2020-05-31 Filed 2020-06-29
10-Q 2020-02-29 Filed 2020-04-03
10-Q 2019-11-30 Filed 2020-01-09
10-K 2019-08-31 Filed 2019-11-14
10-Q 2019-05-31 Filed 2019-07-08
10-Q 2019-02-28 Filed 2019-04-15
10-Q 2018-11-30 Filed 2019-01-11
10-K 2018-08-31 Filed 2018-11-14
10-Q 2018-05-31 Filed 2018-07-13
10-Q 2018-02-28 Filed 2018-04-12
10-Q 2017-11-30 Filed 2018-01-12
10-K 2017-08-31 Filed 2017-11-27
10-Q 2017-05-31 Filed 2017-07-14
10-Q 2017-02-28 Filed 2017-04-14
10-Q 2016-11-30 Filed 2017-01-13
10-K 2016-08-31 Filed 2016-11-29
10-Q 2016-05-31 Filed 2016-07-13
10-Q 2016-02-29 Filed 2016-04-13
10-Q 2015-11-30 Filed 2016-01-08
10-K 2015-08-31 Filed 2015-11-27
10-Q 2015-05-31 Filed 2015-07-14
10-Q 2015-02-28 Filed 2015-04-14
10-Q 2014-11-30 Filed 2015-01-14
10-Q 2014-07-31 Filed 2014-09-11
10-Q 2014-04-30 Filed 2014-06-12
10-Q 2014-01-31 Filed 2014-03-12
10-K 2013-10-31 Filed 2014-01-24
10-Q 2013-07-31 Filed 2013-09-10
10-Q 2013-04-30 Filed 2013-06-12
10-Q 2013-01-31 Filed 2013-03-13
10-K 2012-10-31 Filed 2013-01-29
10-Q 2012-07-31 Filed 2012-09-12
10-Q 2012-04-30 Filed 2012-06-07
10-Q 2012-01-31 Filed 2012-03-13
10-K 2011-10-31 Filed 2012-01-30
10-Q 2011-07-31 Filed 2011-09-14
10-Q 2011-04-30 Filed 2011-06-13
10-Q 2011-01-31 Filed 2011-03-15
10-K 2010-10-31 Filed 2011-01-31
10-Q 2010-07-31 Filed 2010-09-07
10-Q 2010-04-30 Filed 2010-06-01
10-Q 2010-01-31 Filed 2010-03-15
10-K 2009-10-31 Filed 2010-01-20
8-K 2020-11-18
8-K 2020-11-05
8-K 2020-08-07
8-K 2020-07-08
8-K 2020-06-29
8-K 2020-06-23
8-K 2020-05-04
8-K 2020-03-19
8-K 2020-02-28
8-K 2020-01-14
8-K 2020-01-09
8-K 2019-11-28
8-K 2019-11-13
8-K 2019-08-27
8-K 2019-08-14
8-K 2019-08-01
8-K 2019-07-23
8-K 2019-07-11
8-K 2019-06-20
8-K 2019-06-04
8-K 2019-05-15
8-K 2019-04-29
8-K 2019-04-15
8-K 2019-04-05
8-K 2019-03-20
8-K 2019-01-28
8-K 2019-01-15
8-K 2019-01-15
8-K 2018-12-14
8-K 2018-12-07
8-K 2018-11-26
8-K 2018-11-13
8-K 2018-10-31
8-K 2018-10-16
8-K 2018-10-10
8-K 2018-09-07
8-K 2018-08-30
8-K 2018-08-07
8-K 2018-07-31
8-K 2018-07-03
8-K 2018-06-29
8-K 2018-06-20
8-K 2018-05-28
8-K 2018-05-23
8-K 2018-04-27
8-K 2018-04-25
8-K 2018-04-17
8-K 2018-04-11
8-K 2018-03-23
8-K 2018-03-20
8-K 2018-03-13
8-K 2018-02-27
8-K 2018-02-02
8-K 2018-01-25
8-K 2018-01-17
8-K 2018-01-08

Lexaria Bioscience Financials

LXRP Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Aries I Acquisition Corp. (RAMMU)
024 Pharma (EEIG)
Beauty Health Co (VSPRW)
Aquarius I Acquisition Corp. (AQUI)
MIZUHO FINANCIAL GROUP INC (MZHOF)
Eucrates Biomedical Acquisition Corp. (EUCRW)
11 Good Energy (ELVN)
180 Life Sciences Corp. (ATNFW)
1347 Capital Corp (TFSC)
Avanti Acquisition Corp. (AVAN-WT)
CORDIA CORP (CORG)
FCCC INC (FCIC)
Biofrontera Inc. (BFRI)
Ameren Illinois Co (AILNP)
MITSUBISHI UFJ FINANCIAL GROUP INC (MBFJF)
Janus International Group, Inc. (JBI-WT)
23andMe Holding Co. (MEUSW)
OceanTech Acquisitions I Corp. (OTECU)
Palayan Resources, Inc. (PLYN)
ALABAMA POWER CO (APRCP)

Balance Sheet ($'000)2011-07-312011-10-312012-01-312012-04-302012-07-312012-10-312013-01-312013-04-302013-07-312013-10-312014-01-312014-04-302014-07-312014-11-302015-02-282015-05-312015-08-312015-11-302016-02-292016-05-312016-08-312016-11-302017-02-282017-05-312017-08-312017-11-302018-02-282018-05-312018-08-312018-11-302019-02-282019-05-31
Cash49431140121161813945286629952578431792832260844037931245242,7892,5332,2102,3182,0631,7272,6453,0931,996
Accounts Receivable23223117614049829124016715279131100997535223135441513164924574572188268266215219226
Inventory1978791681881411271351501431286777637687117108188
PP&E00333222222211123633607
Assets3,8654,3394,2284,1314,2244,1923,9233,7993,6833,5733,5604,8384,5662,2511,2101,1997124963893315671,1378693,1442,8602,4972,8412,7092,4323,5444,2743,457
Accounts Payable16087
Long-Term Debt
Liabilities1,4761,6781,6761,8111,8361,7711,6141,5381,4581,4741,5331,1051,017835666355177284377479514379859296697244130500132
Stockholders' Equity2,3892,6612,5522,3202,3882,4212,3092,2622,2252,0992,0273,7333,5501,4161,1451,1527724642651212668076913,2653,0062,4022,7722,6372,3883,4143,7733,325
Income Statement ($'000)2011-07-312011-10-312012-01-312012-04-302012-07-312012-10-312013-01-312013-04-302013-07-312013-10-312014-01-312014-04-302014-07-312014-11-302015-02-282015-05-312015-08-312015-11-302016-02-292016-05-312016-08-312016-11-302017-02-282017-05-312017-08-312017-11-302018-02-282018-05-312018-08-312018-11-302019-02-282019-05-31
Revenue3751115699132925172140221560
Cost of Revenue185-37145143229266223165175232127110822101814199311596142233
Gross Profit1741651042265203128887693358541-3-14-4-4-368-22081915813893201357
R&D48009827007883111076932149766231
SG&A18531115343123665356106811046027715428318822514024191245165197
Tax000000000140
Net Income-2531-119-232-412-1,227-701-1,153-1,188
Cash Flow ($'000)2011-07-312011-10-312012-01-312012-04-302012-07-312012-10-312013-01-312013-04-302013-07-312013-10-312014-01-312014-04-302014-07-312014-11-302015-02-282015-05-312015-08-312015-11-302016-02-292016-05-312016-08-312016-11-302017-02-282017-05-312017-08-312017-11-302018-02-282018-05-312018-08-312018-11-302019-02-282019-05-31
Cash Operating-12-46-7048204621246074-92-97-223-173-361-386-581-209-83-108-261-101-488-604-353-520-601-560-837-564-603-1,101
Cash Investing-417-450-202-27-37-27-0-6-25-31-520722-414-3-12-0-5-14400-86-16-27-27-167-336-233
Cash Financing-352005050-12-167-91-77-30801,051-99-990467536511063221468832,869982827253325281,6493811,243